Heartbeat: higher risk of COVID-19 infection in younger patients with cardiovascular disease
In: Heart, 2021-02-11
Online
unknown
Zugriff:
Cardiovascular disease (CVD) is a major risk factor for adverse outcomes with COVID-19 infection. Concerns raised early in the pandemic that renin-angiotensin system (RAS) blockade by treatment with angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers might increase that risk have not been supported by observational studies and meta-analyses.1 2 As Simon and Danchin3 point out, ‘jumping to therapeutic conclusions on the sole basis of pathophysiological or experimental considerations is hazardous. Nature can be tricky, and pathways that are blocked by a therapeutic intervention are often short-circuited by other, secondary, pathways that will result in the lack of clinical effect of the said therapeutic intervention. Here, in spite of the recognised interference between ACE2 and SARS-CoV-2, and of the possible link between RAS blockers and ACE2 in humans, these medications appeared clinically neutral.’ Age also is a major risk factor for COVID-19 infection, with previous analyses treating age as a potential confounder. While this approach often is appropriate, treating age as a confounder might obscure any differences in risk among younger and older patients with CVD. In order to examine the effect of age on the risk of fatal outcomes with COVID-19 infection in patients with CVD, Bae and colleagues4 performed a meta-analysis of 51 studies including …
Titel: |
Heartbeat: higher risk of COVID-19 infection in younger patients with cardiovascular disease
|
---|---|
Autor/in / Beteiligte Person: | Catherine M Otto |
Link: | |
Zeitschrift: | Heart, 2021-02-11 |
Veröffentlichung: | BMJ, 2021 |
Medientyp: | unknown |
ISSN: | 1468-201X (print) ; 1355-6037 (print) |
DOI: | 10.1136/heartjnl-2021-319052 |
Schlagwort: |
|
Sonstiges: |
|